Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Bayer AG
Woman and Man Max 99 years
Bayer AG
Update Il y a 4 ans
Investigation of the change of vision-related quality of life in subjects treated with aflibercept according to EU label for DME
To evaluate the change in quality of life (NEI VFQ 25) in subjects with DME during the first year of treatment with aflibercept according to the EU label for DME
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 4 ans
Rivaroxaban versus Aspirin in secondary prevention of stroke and prevention of systemic embolism in patients with recent embolic stroke of undetermined source (ESUS)
The primary efficacy objective is to evaluate whether rivaroxaban is superior to aspirin in reducing the risk of recurrent stroke and systemic embolism in patients with a recent ESUS.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 4 ans
Efficacy and safety of three different aflibercept regimens in subjects with DME
The primary objective of this study is to evaluate the efficacy of long-term treatment with 2 mg aflibercept via different intravitreal (IVT) treatment regimens to subjects with DME pre-treated for at...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 4 ans
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (non–CF BE)
The primary objectives of this study are • To evaluate the efficacy of ciprofloxacin DPI administered BID intermittently for 28 days on study treatment / 28 days off study treatment or 14 days on stud...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4